Nasus Pharma specializes in the development of intranasal drug delivery systems, focusing on powder-based formulations designed to address acute medical conditions and public health emergencies. Their proprietary Nasax® platform utilizes unique microsphere technology, which has demonstrated significantly higher absorption rates compared to traditional liquid formulations. Clinical studies have shown that their intranasal powder products achieve up to seven times higher absorption within the first four minutes and four times higher absorption within the first ten minutes. This rapid delivery mechanism is particularly advantageous in emergency situations where immediate drug action is critical.

The intranasal delivery method offers several benefits, including non-invasive administration, quick access to the bloodstream, and the ability to bypass the blood-brain barrier, making it suitable for conditions requiring urgent treatment. Nasus Pharma's formulations are designed to be safe and effective, with a focus on stability and longer shelf life. The technology employs uniform spherical active pharmaceutical ingredients (APIs) combined with larger lactose particles that facilitate the delivery process, ensuring consistent and reliable absorption. This innovative approach has the potential to significantly improve patient outcomes in life-threatening scenarios, such as severe allergic reactions and opioid overdoses.

Israel

Nasus pharma develops Powder-Based Intranasal (PBI) specialized product portfolio to address acute medical conditions & public health threats.

Nasus Pharma

Company Details